Clinical Trials Browser

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT03674567 2025-01-24

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

Phase 1/2 Completed

323 enrolled

BreastGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Lymphoma

NCT05878691 2024-07-22

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Phase 1 Active not recruiting

320 enrolled

Lymphoid

Lymphoma

NCT03934814 2024-07-01

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Phase 1 Completed

98 enrolled

Lymphoid

Lymphoma

NCT04541108 2024-04-18

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Phase EARLY_PHASE1 Recruiting

15 enrolled

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT04920383 2024-03-01

NEON-2

Phase 1 Terminated

29 enrolled

Lymphoid

Lymphoma

NCT04609579 2024-01-30

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Phase 1 Terminated

27 enrolled

GastrointestinalGynecologicLymphoid

Bites and Stings, Lymphoma, Ovarian Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell

NCT05296772 2023-09-06

Phase 1 First-in-human Study of JS014

Phase 1 Unknown

60 enrolled

Lymphoid

Lymphoma, Neoplasms, Neoplasms, Experimental

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

159 enrolled

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03815682 2022-12-06

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

Phase 1 Terminated

23 enrolled

DermatologicLymphoid

Lymphoma, Melanoma

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Phase 1/2 Completed

444 enrolled 19 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01986426 2018-10-03

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Phase 1 Completed

80 enrolled

BreastDermatologicHead & NeckLymphoid

Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

MK-3475-051

MK-3475-G21

MK-1454-001

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

IT-01

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

NEON-2

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Phase 1 First-in-human Study of JS014

Safety Study of SEA-CD40 in Cancer Patients

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab